CL2020003032A1 - Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos. - Google Patents
Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos.Info
- Publication number
- CL2020003032A1 CL2020003032A1 CL2020003032A CL2020003032A CL2020003032A1 CL 2020003032 A1 CL2020003032 A1 CL 2020003032A1 CL 2020003032 A CL2020003032 A CL 2020003032A CL 2020003032 A CL2020003032 A CL 2020003032A CL 2020003032 A1 CL2020003032 A1 CL 2020003032A1
- Authority
- CL
- Chile
- Prior art keywords
- monospecific
- multispecific anti
- tmeff2 antibodies
- antibodies
- tmeff2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675957P | 2018-05-24 | 2018-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003032A1 true CL2020003032A1 (es) | 2021-04-16 |
Family
ID=67211771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003032A CL2020003032A1 (es) | 2018-05-24 | 2020-11-23 | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866499B2 (enExample) |
| EP (1) | EP3802607A2 (enExample) |
| JP (2) | JP2021524255A (enExample) |
| KR (1) | KR20210011999A (enExample) |
| CN (1) | CN112703203B (enExample) |
| AR (1) | AR115419A1 (enExample) |
| AU (1) | AU2019274652B2 (enExample) |
| BR (1) | BR112020023416A2 (enExample) |
| CA (1) | CA3101304A1 (enExample) |
| CL (1) | CL2020003032A1 (enExample) |
| CO (1) | CO2020014515A2 (enExample) |
| CR (1) | CR20200564A (enExample) |
| EA (1) | EA202092849A1 (enExample) |
| EC (1) | ECSP20075234A (enExample) |
| IL (1) | IL278862A (enExample) |
| JO (1) | JOP20200295A1 (enExample) |
| MA (1) | MA52772A (enExample) |
| MX (1) | MX2020012589A (enExample) |
| NI (1) | NI202000087A (enExample) |
| PE (1) | PE20210634A1 (enExample) |
| PH (1) | PH12020551948A1 (enExample) |
| SG (1) | SG11202011268VA (enExample) |
| TW (1) | TWI865451B (enExample) |
| UY (1) | UY38243A (enExample) |
| WO (1) | WO2019224713A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| PH12022551470A1 (en) * | 2019-12-18 | 2023-05-03 | Janssen Biotech Inc | Materials and methods for in vivo biological targeting |
| PE20230389A1 (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| US20230374140A1 (en) * | 2020-10-09 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4583980A1 (en) * | 2022-09-09 | 2025-07-16 | Janssen Biotech, Inc. | Method of treating cancer with an anti tmeff2xcd3 bispecific antibody |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US226A (en) | 1837-06-03 | Samuel goss | ||
| US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| WO2003075855A2 (en) | 2002-03-08 | 2003-09-18 | Protein Design Labs, Inc. | Antibodies against cancer antigen tmeff2 and uses thereof |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| BRPI0818780A2 (pt) * | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US20150030602A1 (en) | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| PT2970980T (pt) | 2013-03-15 | 2018-11-19 | Janssen Biotech Inc | Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| DK3189081T3 (da) | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| EP3778640A1 (en) * | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| EP3310811B1 (en) * | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
-
2019
- 2019-05-21 EA EA202092849A patent/EA202092849A1/ru unknown
- 2019-05-21 EP EP19737217.0A patent/EP3802607A2/en active Pending
- 2019-05-21 CR CR20200564A patent/CR20200564A/es unknown
- 2019-05-21 JO JOP/2020/0295A patent/JOP20200295A1/ar unknown
- 2019-05-21 US US16/417,889 patent/US11866499B2/en active Active
- 2019-05-21 BR BR112020023416-8A patent/BR112020023416A2/pt unknown
- 2019-05-21 AU AU2019274652A patent/AU2019274652B2/en active Active
- 2019-05-21 KR KR1020207036922A patent/KR20210011999A/ko not_active Ceased
- 2019-05-21 CN CN201980034951.1A patent/CN112703203B/zh active Active
- 2019-05-21 WO PCT/IB2019/054184 patent/WO2019224713A2/en not_active Ceased
- 2019-05-21 CA CA3101304A patent/CA3101304A1/en active Pending
- 2019-05-21 MX MX2020012589A patent/MX2020012589A/es unknown
- 2019-05-21 PE PE2020001881A patent/PE20210634A1/es unknown
- 2019-05-21 MA MA052772A patent/MA52772A/fr unknown
- 2019-05-21 SG SG11202011268VA patent/SG11202011268VA/en unknown
- 2019-05-21 JP JP2020565399A patent/JP2021524255A/ja active Pending
- 2019-05-22 TW TW108117613A patent/TWI865451B/zh active
- 2019-05-24 AR ARP190101399A patent/AR115419A1/es not_active Application Discontinuation
- 2019-05-24 UY UY0001038243A patent/UY38243A/es unknown
-
2020
- 2020-11-13 PH PH12020551948A patent/PH12020551948A1/en unknown
- 2020-11-19 IL IL278862A patent/IL278862A/en unknown
- 2020-11-23 NI NI202000087A patent/NI202000087A/es unknown
- 2020-11-23 EC ECSENADI202075234A patent/ECSP20075234A/es unknown
- 2020-11-23 CL CL2020003032A patent/CL2020003032A1/es unknown
- 2020-11-23 CO CONC2020/0014515A patent/CO2020014515A2/es unknown
-
2024
- 2024-05-09 JP JP2024076617A patent/JP2024105476A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL278862A (en) | 2021-01-31 |
| AU2019274652B2 (en) | 2026-03-26 |
| SG11202011268VA (en) | 2020-12-30 |
| UY38243A (es) | 2019-11-29 |
| AU2019274652A1 (en) | 2020-11-26 |
| NI202000087A (es) | 2021-03-23 |
| TWI865451B (zh) | 2024-12-11 |
| JP2021524255A (ja) | 2021-09-13 |
| MX2020012589A (es) | 2021-01-29 |
| CR20200564A (es) | 2021-06-21 |
| PE20210634A1 (es) | 2021-03-23 |
| JOP20200295A1 (ar) | 2020-11-22 |
| US11866499B2 (en) | 2024-01-09 |
| JP2024105476A (ja) | 2024-08-06 |
| US20190359711A1 (en) | 2019-11-28 |
| CO2020014515A2 (es) | 2020-12-10 |
| WO2019224713A2 (en) | 2019-11-28 |
| PH12020551948A1 (en) | 2021-08-16 |
| CN112703203B (zh) | 2025-02-25 |
| ECSP20075234A (es) | 2020-12-31 |
| CA3101304A1 (en) | 2019-11-28 |
| EA202092849A1 (ru) | 2021-03-16 |
| TW202003584A (zh) | 2020-01-16 |
| EP3802607A2 (en) | 2021-04-14 |
| KR20210011999A (ko) | 2021-02-02 |
| CN112703203A (zh) | 2021-04-23 |
| BR112020023416A2 (pt) | 2021-02-17 |
| MA52772A (fr) | 2021-04-14 |
| WO2019224713A3 (en) | 2020-01-02 |
| AR115419A1 (es) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014515A2 (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
| ECSP19050049A (es) | Anticuerpos anti-ox40 y sus usos | |
| CO2021008568A2 (es) | Anticuerpos que se unen a cd3 | |
| AR133470A2 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
| CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
| CO2019007092A2 (es) | Receptores inmunes sintéticos y métodos de uso de los mismos | |
| CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
| MX2018014630A (es) | Anticuerpos anti-cd40 y sus usos. | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| CL2017003356A1 (es) | Moduladores cot y métodos de uso de los mismos | |
| UY40770A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de éstas | |
| TR2021016542A2 (tr) | Plazma bazlı filmler ve bunları üretme ve kullanma usulleri. | |
| AR114001A1 (es) | Anticuerpos que se unen a hla- a2 / wt1 | |
| ECSP14005975A (es) | Anticuerpos anti-PHF-tau y sus usos | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| MX2019015868A (es) | Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima. | |
| AR120093A1 (es) | Anticuerpos anti-ceacam y usos de los mismos | |
| MX2020002552A (es) | Métodos y composiciones para preparar proteína surfactante d (sp-d). | |
| DOP2017000264A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
| AR113695A1 (es) | Una d-psicosa 3-epimerasa y el uso de un método para producir d-psicosa | |
| CL2016001884A1 (es) | Método para sintetizar florfenicol. |